ADALIMUMAB ADALIMUMAB (12389C) adalimumab 40 mg/0.4 mL injection, 2 x 0.4 mL pen devices 12389C Body System: Antineoplastic And Immunomodulating Agents > Immunosuppressants > Immunosuppressants Manner of administration:Injection General Schedule Authority Required Restriction Indication: Severe Crohn disease Treatment phase: Continuing treatment Quantities & Cost Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge Max qty packs: 1 Max qty units: 2 # of repeats: 5 DPMQ: $495.79 Max safety net: $25.00 General Patient Charge: $25.00 Available brands Hadlima Humira Hyrimoz Yuflyma
